FOUGERA PHARMS — Patent Portfolio
1 drug with active patents · 8 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict The FOUGERA PHARMS portfolio is relatively weak with a high average vulnerability score, and the company faces a significant cliff year in 2028 with 1 drug losing exclusivity.
Portfolio overview The FOUGERA PHARMS portfolio consists of a total of 3 drugs, with 1 of them having patents. The company has a total of 8 US patents, all of which are active. The average vulnerability score of the portfolio is 50, indicating a relatively high risk of patent challenges. There are no ironclad patents, and no vulnerable patents in the portfolio.
Cliff calendar The FOUGERA PHARMS portfolio faces a significant cliff year in 2028, with 1 drug losing exclusivity. This includes Temovate, which will lose exclusivity on November 5, 2028.
Most exposed drugs The top drug facing near-term loss of exclusivity is Temovate, with an earliest active patent expiry date of November 5, 2028, an average vulnerability score of 50, and no annual revenue data available. This drug has 8 patents and is a significant contributor to the company's portfolio.
Biologic exclusivity There are no biologics in the FOUGERA PHARMS portfolio, and therefore, there is no BPCIA 12-year reference product exclusivity to consider.
Strategic implications The FOUGERA PHARMS portfolio faces a total revenue at risk of $0 in the next 5 years, as there are no biologics or drugs with significant revenue data available. The company should consider lifecycle moves such as subQ switches, label extensions, and combination filings to maintain revenue and competitiveness.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Temovate (CLOBETASOL PROPIONATE)
Cliff 2028 · 2y-
US11179465
Vuln 64
2030-08-31
This patent protects topical compositions that include a corticosteroid, at least one alcohol, and a penetration-enhancing agent.
-
US8460641
Vuln 63
2028-11-05
This patent protects a microemulsion composition for dermal delivery of a pharmaceutically active ingredient, including an occlusive agent and surfactants.
-
US11376262
Vuln 58
2036-05-09
This patent protects a method of treating an inflammatory or infectious disease by administering an aqueous suspension of nanoparticles of a glucocorticosteroid compound.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 6 patents
- Formulation 2 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track FOUGERA PHARMS's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export